Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 8 EP applications Rudolf Schneider has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after February 23, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11306400

Gene cluster for biosynthesis of griselimycin and methylgriselimycin

IPC classification:
C07K 14/36, C12R 1/465
Applicant:
Sanofi, S.A.
Agent:
Rudolf Schneider, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION REFUSED
EP12306043

Combination treatments involving antibodies to human PCSK9

IPC classification:
A61K 39/395, C07K 16/40
Applicant:
Sanofi, S.A.
Agent:
Rudolf Schneider, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION REFUSED
EP12306068

Combination treatments involving antibodies to human PCSK9

IPC classification:
A61K 39/395, C07K 16/40
Applicant:
Sanofi, S.A.
Agent:
Rudolf Schneider, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION REFUSED
EP11305088

Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)

IPC classification:
A61K 31/00, A61K 39/395
Applicant:
Sanofi, S.A.
Agent:
Rudolf Schneider, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION REFUSED
EP11721769

METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA

IPC classification:
C12Q 1/68, G01N 33/50
Applicant:
Sanofi, S.A.
Agent:
Kathrin Körner, Zwicker Schnappauf & Partner Patentanwälte PartG mbB (ZSP)
Agent:
Multiple attorneys, Sanofi-Aventis Deutschland GmbH
Agent:
Kathrin Körner, 2SPL Patentanwälte PartG mbB
Status:
APPLICATION WITHDRAWN
EP12306039

Human antibodies to PCSK9 for use in methods of treating particular groups of subjects

IPC classification:
A61K 39/395, C07K 5/02, C07K 16/40
Applicant:
Sanofi, S.A.
Agent:
Rudolf Schneider, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION REFUSED
EP11306712

Method for recombinant production of labyrinthopeptins and functional derivatives thereof

IPC classification:
A61K 38/16, C07K 14/36, C12N 15/76
Applicant:
Sanofi, S.A.
Agent:
Rudolf Schneider, Sanofi-Aventis Deutschland GmbH
Status:
APPLICATION REFUSED
EP11721069

METHODS OF DIAGNOSING ALGESIA

IPC classification:
C12Q 1/68
Applicant:
Sanofi, S.A.
Applicant:
Sanofi
Agent:
Rudolf Schneider, Sanofi-Aventis Deutschland GmbH
Status:
PATENT GRANTED

Please Sign in to use this feature